{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:59:33Z","timestamp":1789390773812,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.leukres.2008.06.006","type":"journal-article","created":{"date-parts":[[2008,7,17]],"date-time":"2008-07-17T00:24:55Z","timestamp":1216254295000},"page":"67-73","source":"Crossref","is-referenced-by-count":87,"title":["Is JAK2 V617F mutation more than a diagnostic index?"],"prefix":"10.1016","volume":"33","author":[{"given":"Issa J.","family":"Dahabreh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Zoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula","family":"Giannouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Zoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Loukopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Voulgarelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2008.06.006_bib1","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.006_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2007.12.007","article-title":"Hypereosinophilic syndrome: another face of Janus?","author":"Dahabreh","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2008.06.006_bib3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/MD.0b013e31815d108c","article-title":"Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics","volume":"86","author":"Dahabreh","year":"2007","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.leukres.2008.06.006_bib4","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and myelodysplastic syndromes","volume":"106","author":"Steensma","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.006_bib5","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/sj.leu.2403902","article-title":"Clinical implications of the JAK2 V617F mutation in essential thrombocythemia","volume":"19","author":"Antonioli","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.06.006_bib6","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.22663","article-title":"Clinical correlates of JAK2V617F allele burden in essential thrombocythemia","volume":"109","author":"Kittur","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2008.06.006_bib7","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2008.06.006_bib8","doi-asserted-by":"crossref","first-page":"11156","DOI":"10.1158\/0008-5472.CAN-06-2210","article-title":"Characterization of murine JAK2V617F-positive myeloproliferative disease","volume":"66","author":"Bumm","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2008.06.006_bib9","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis","volume":"108","author":"Lacout","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.006_bib10","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model","volume":"107","author":"Wernig","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.006_bib11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.leukres.2008.06.006_bib12","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.leukres.2008.06.006_bib13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.leukres.2008.06.006_bib14","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.leukres.2008.06.006_bib15","first-page":"690","article-title":"Chi-square tests with one degree of freedom: extensions of the Mantel\u2013Haenszel procedure","volume":"58","author":"Mantel","year":"1963","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.leukres.2008.06.006_bib16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.leukres.2008.06.006_bib17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/1740774508090212","article-title":"Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone","volume":"5","author":"Dahabreh","year":"2008","journal-title":"Clin Trials"},{"key":"10.1016\/j.leukres.2008.06.006_bib18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.leukres.2008.06.006_bib19","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/0003-4819-127-9-199711010-00008","article-title":"Quantitative synthesis in systematic reviews","volume":"127","author":"Lau","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.leukres.2008.06.006_bib20","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2008.06.006_bib21","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2005.05858.x","article-title":"The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia","volume":"132","author":"Cheung","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.06.006_bib22","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2353\/jmoldx.2006.050128","article-title":"Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases","volume":"8","author":"Horn","year":"2006","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.leukres.2008.06.006_bib23","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-0609.2006.00688.x","article-title":"JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status","volume":"77","author":"Heller","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2008.06.006_bib24","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1080\/00313020600820906","article-title":"Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood","volume":"38","author":"Stevenson","year":"2006","journal-title":"Pathology"},{"key":"10.1016\/j.leukres.2008.06.006_bib25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3343\/kjlm.2007.27.2.77","article-title":"JAK2(V617F) mutation in Korean patients with essential thrombocythemia","volume":"27","author":"Ahn","year":"2007","journal-title":"Korean J Lab Med"},{"key":"10.1016\/j.leukres.2008.06.006_bib26","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/sj.leu.2404693","article-title":"Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients","volume":"21","author":"Alvarez-Larran","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.06.006_bib27","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1556\/OH.2007.27860","article-title":"Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection","volume":"148","author":"Andrikovics","year":"2007","journal-title":"Orv Hetil"},{"key":"10.1016\/j.leukres.2008.06.006_bib28","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.exphem.2007.08.011","article-title":"The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia","volume":"35","author":"Hsiao","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2008.06.006_bib29","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance","volume":"131","author":"Wolanskyj","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.06.006_bib30","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.leu.2404604","article-title":"JAK2(V617F) mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders","volume":"21","author":"Ohyashiki","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.06.006_bib31","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/sj.leu.2404755","article-title":"The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis","volume":"21","author":"Pemmaraju","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.06.006_bib32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1532\/IJH97.E0607","article-title":"The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more \u201cerythremic\u201d and less \u201cthrombocythemic\u201d: a molecular, histologic, and clinical study","volume":"86","author":"Rudzki","year":"2007","journal-title":"Int J Hematol"},{"key":"10.1016\/j.leukres.2008.06.006_bib33","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.leukres.2006.09.005","article-title":"Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders","volume":"31","author":"Speletas","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2008.06.006_bib34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2007.06755.x","article-title":"JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets","volume":"139","author":"Toyama","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.06.006_bib35","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.006_bib36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3324\/haematol.11653","article-title":"Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia","volume":"93","author":"Antonioli","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.06.006_bib37","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0895-4356(00)00242-0","article-title":"Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature","volume":"53","author":"Sterne","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.leukres.2008.06.006_bib38","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.006_bib39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.06.006_bib40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1055\/s-2007-976166","article-title":"Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk","volume":"33","author":"Barbui","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.leukres.2008.06.006_bib41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2007-976165","article-title":"Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F","volume":"33","author":"Tefferi","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.leukres.2008.06.006_bib42","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2006-10-054940","article-title":"The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera","volume":"110","author":"Dupont","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.006_bib43","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1073\/pnas.0601462103","article-title":"The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation","volume":"103","author":"Jamieson","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2008.06.006_bib44","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","article-title":"Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status","volume":"109","author":"Carobbio","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.006_bib45","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1182\/blood-2007-01-066985","article-title":"The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia","volume":"109","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.006_bib46","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.exphem.2007.01.053","article-title":"V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules","volume":"35","author":"Falanga","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2008.06.006_bib47","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood.V96.13.4261","article-title":"Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera","volume":"96","author":"Falanga","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.006_bib48","first-page":"169","article-title":"Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status","volume":"91","author":"Arellano-Rodrigo","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.06.006_bib49","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00062752-200303000-00009","article-title":"Cell-cell interactions: leukocyte\u2013endothelial interactions","volume":"10","author":"McIntyre","year":"2003","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.leukres.2008.06.006_bib50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2008.06.006_bib51","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMe058093","article-title":"When and how to treat essential thrombocythemia","volume":"353","author":"Barbui","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2008.06.006_bib52","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1111\/j.1538-7836.2006.02194.x","article-title":"Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?","volume":"4","author":"Maugeri","year":"2006","journal-title":"J Thromb Haemost"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608002853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608002853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T01:53:19Z","timestamp":1588816399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212608002853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S0145212608002853"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2008.06.006","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}